China beats the U.S. in global approval ratings by the biggest margin ever.

China’s median global approval rose to 36% in 2025 versus the U.S. at 31%, a 13-percentage-point increase for China and a 21-point decline for the U.S. from 2024; U.S. disapproval hit a record-high 48% while China’s disapproval remained at 37%. Germany led at 48% approval and Russia trailed at 26%; Israel’s approval of U.S. leadership rose to 76%. Gallup surveyed respondents in more than 130 countries and notes the data predates the U.S. withdrawal from 66 international organizations and the start of the Iran war, highlighting potential shifts in geopolitical risk perceptions relevant to policymakers and investors.

Analysis

A durable uptick in global sentiment toward China lowers the political friction premium for overseas infrastructure, telecom and energy contracts; that translates into faster award and financing cycles for SOEs and state-backed banks over 6–24 months as host-country objections fall and multilateral lenders tacitly align. Expect incremental revenue acceleration to be concentrated in engineered goods and project finance — sectors with long tails (3–7 year revenue recognition) that can re-rate independently of China’s domestic cyclical story.

The primary near-term reversal risks are policy pivots and exogenous shocks: a rapid US diplomatic rebound (re‑entry to key institutions or major summit outcomes) or a regional conflict that re‑polarizes allies could flip sentiment inside weeks to months. Watchables that will presage either outcome include the cadence of bilateral MOUs, syndicated export-credit facilities denominated in RMB, and changes in host-country FX reserve allocations — these typically lead real activity by 3–9 months.

Actionable positioning should overweight Chinese international exporters and EM recovery beta while hedging geopolitical regime risk: buy structural exposure via large-cap China ETFs and selectively add single-name longs in listed contractors with high export mix; hedge with short-dated options or an allocation to global safety assets to protect vs headline tail events. Position sizing should be tournament-style: modest initial sized entries with optionality-based add-ons on confirmed contract wins or policy clarifications over the next 6–12 months.

The consensus underprices regulatory and capital-control asymmetry: improved favorability doesn’t erase onshore policy levers that can cap capital returns. Therefore, trades should tilt toward export/FX-earning businesses and use liquid ETFs or traded options to control execution and tail risk rather than large direct exposures to domestically focused names.

Key Decisions for Investors

• Initiate a 6–12 month tactical long: FXI (iShares China Large‑Cap) 3% portfolio weight. Rationale: captures SOE/export upside from smoother overseas deal flow. Risk/reward: downside -15% on renewed regulatory shock; target +25% if export awards and RMB flows accelerate; add on evidence of new outbound project financings.
• Buy ASHR (Xtrackers Harvest CSI 300 A‑Share ETF) 12‑month call spread (buy 1, sell 1 higher strike) sized to 1–2% portfolio. Rationale: directional China A upside with defined max loss via spread. Reward vs risk ~3:1 if A‑share inflows resume; protects against sudden onshore intervention.
• Pair trade (6–18 months): long EEM 2% / short a US consumer discretionary ETF 1% (XLY) to express EM/China sentiment outperformance vs US domestic cyclical exposure. Rationale: political headwinds to US soft power may depress discretionary cyclical demand in sensitive markets. Expect asymmetric upside in EEM if flows reallocate; cap losses with monthly rebalancing.
• Defensive hedge: add 3–6 month protection via buying LMT or NOC weekly puts sized to 0.5% portfolio if geopolitical headlines spike. Rationale: protects portfolio against sudden conflict escalation that would compress risk assets broadly. Cost is insurance premium; exercise if event risk materializes.